CTRI/2012/01/002358已完成2 期
A prospective phase II study to assess the feasibility, efficacy and tolerance of neoadjuvant Chemotherapy with ultra fractionated radiotherapy prior to definitive chemoradiation in stage IIB, IIIA and IIIB Squamous cell carcinoma of cervix - LDRTCX
Fluid Research Grant CMC Vellore0 个研究点目标入组 20 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •a.Inclusion Criteria:
- •Women with histologically proven diagnosis of squamous cell carcinoma cervix FIGO stage IIB to IIIB will be included in the study. Inclusion criteria
- •1.Age less than or equal to 70 years
- •2.ECOG less than or equal to 2
- •3.Pretreatment Hb more than 9 gm%
- •4.Leucocytes more than or equal to 4000 / mm3
- •5.Platelets more than or equal to 1,00,000/mm3
- •6.Normal hepatic and renal parameters
排除标准
- •Patients with renal, hepatic or cardiac co-morbidities or previous history of chemotherapy/radiation therapy/malignancy will be excluded
研究者
相似试验
招募中
不适用
Clinical study to determine the appropriateness of a starting dose of 160 mg/day of lazertinib in patients with EGFR T790M-positive non-small cell lung cancerNeoplasmsKCT0008332Samsung Medical Center117
进行中（未招募）
1 期
A phase II study evaluating the feasibility and clinical efficacy of atezolizumab consolidation treatment in high risk diffuse large B-cell lymphoma.EUCTR2017-002605-35-BEHOVON Foundation109
进行中（未招募）
1 期
A phase II study evaluating the feasibility and clinical efficacy of atezolizumab consolidation treatment in high risk diffuse large B-cell lymphoma.EUCTR2017-002605-35-NLHOVON Foundation109
招募中
2 期
A phase II study evaluating the feasibility and clinical efficacy of atezolizumab consolidation treatment in high risk diffuse large B-cell lymphomaDiffuse large B-cell lymphoma10025320lymphomaNL-OMON52540HOVO90
进行中（未招募）
1 期
Clinical trial to evaluate the efficacy and the safety of a combination of bendamustine-melphalan as preparative regimen to autologous transplantation of hematopoietic cells for multiple myeloma who did not responded after previous high-dose therapyMultiple myelomaEUCTR2014-000130-37-ITFONDAZIONE NEOPLASIE SANGUE ONLUS (FO.NE.SA. Onlus)73